-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hemophilia is mostly a hereditary disease that prevents the body from clotting and forming a blood clot to stop bleedi.
The Institute for Clinical and Economic Review (ICER) announced that it will evaluate the clinical efficacy and value of EtranaDez (etranacogene dezaparvovec) in the treatment of hemophili.
EtranaDez is an AAV5-mediated gene therapy that delivers the Padua variant of the factor IX gene to liver cells, resulting in an active variant of factor .
The results showed that the annualized bleeding rate (ABR) assessed 18 months after infusion decreased to 51, compared with 19 in the run-in period, meeting the primary noninferiority endpoint as well as secondary endpoin.
Original source:
Original source:https://firstwordphar.
https://firstwordphar.
com/story/5565489 https://firstwordphar.
com/story/5565489Leave a comment here